Lv61
3200 积分 2024-09-23 加入
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
10天前
已关闭
Effects of the DPP-1 inhibitor HSK31858 in adults with bronchiectasis in China (SAVE-BE): a phase 2, multicentre, double-blind, randomised, placebo-controlled trial
24天前
已完结
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
1个月前
已完结
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
1个月前
已完结
Azurocidin-1 in neutrophilic airway disease: marker, mediator, or bridge to precision therapy?
2个月前
已完结
Azurocidin-1 as a mediator of bronchiectasis severity, epithelial defence, and target of dipeptidyl peptidase-1 inhibition: an international, multicohort study
4个月前
已关闭
Ten unanswered questions about dipeptidyl peptidase-1 inhibition in bronchiectasis
5个月前
已完结
Clearing the air: Clarifying data and interpretations from the ASPEN trial of brensocatib in bronchiectasis
5个月前
已完结
[China lymphoma diagnosis and treatment guideline (2026 edition)]
6个月前
已完结
Diffuse Large B-Cell Lymphoma
6个月前
已完结
皖公网安备34019202002308
